Cencora (NYSE:COR) Releases FY 2026 Earnings Guidance

Key Points

• Cencora issued FY 2026 EPS guidance of $17.75–$17.95, broadly in line with the $17.85 analyst consensus; no revenue guidance was provided.
• The company’s latest quarter exceeded expectations, with EPS of $4.48 versus $4.35 expected and revenue of $84.75 billion, up 5.1% year over year. Shares opened down 1.3% at $310.13.
• Cencora announced a quarterly dividend of $0.60 per share and has authorization for a $2 billion share buyback. Analysts maintain a “Moderate Buy” consensus with an average price target of $374.25.

Cencora (NYSE:COR - Get Free Report) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 17.750-17.950 for the period, compared to the consensus earnings per share estimate of 17.850. The company issued revenue guidance of -.

Cencora Stock Down 1.3%

COR opened at $310.13 on Friday. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. The firm has a 50 day moving average price of $298.20 and a 200-day moving average price of $313.24. The stock has a market capitalization of $60.34 billion, a price-to-earnings ratio of 23.04, a PEG ratio of 1.81 and a beta of 0.57. Cencora has a twelve month low of $244.82 and a twelve month high of $377.54.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping analysts' consensus estimates of $4.35 by $0.13. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The firm had revenue of $84.75 billion during the quarter, compared to analysts' expectations of $84.31 billion. During the same period in the previous year, the company earned $4.00 EPS. The firm's revenue for the quarter was up 5.1% compared to the same quarter last year. Equities research analysts forecast that Cencora will post 17.84 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 14th. Cencora's dividend payout ratio is 17.83%.

Cencora declared that its Board of Directors has initiated a stock buyback program on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 3.9% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on COR. Bank of America increased their target price on Cencora from $280.00 to $285.00 and gave the stock a "neutral" rating in a research report on Wednesday, June 24th. Weiss Ratings upgraded shares of Cencora from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, August 6th. Robert W. Baird set a $370.00 target price on shares of Cencora in a research report on Thursday, August 6th. UBS Group raised their target price on shares of Cencora from $412.00 to $430.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Finally, Evercore reiterated an "outperform" rating and issued a $350.00 price target on shares of Cencora in a research note on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Cencora has an average rating of "Moderate Buy" and a consensus price target of $374.25.

Insider Transactions at Cencora

In related news, Director Lauren M. Tyler purchased 550 shares of the business's stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the acquisition, the director owned 4,359 shares of the company's stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.38% of the company's stock.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Wells Fargo issued a Buy rating on Cencora, providing a fresh bullish signal and potentially supporting the stock’s valuation. Wells Fargo Gives a Buy Rating to Cencora
• Positive Sentiment: Brokerage coverage remains broadly constructive, with Cencora receiving an average “Moderate Buy” rating. Several recent price targets are above the current trading level, and Zacks highlighted the stock as a potential long-term value opportunity. Cencora Receives Moderate Buy Rating Why Cencora Is a Top Value Stock
• Positive Sentiment: Long-term momentum arguments remain intact, supported by Cencora’s healthcare-distribution scale, recurring demand and recent earnings that exceeded consensus expectations for both revenue and adjusted EPS. Why Cencora Is a Top Momentum Stock
• Neutral Sentiment: Analysts focused on customer concentration, pricing changes, GLP-1 demand and the outlook during Cencora’s earnings call. The questions underscore areas investors are monitoring but did not establish a new major catalyst. Five Analyst Questions From Cencora’s Earnings Call
• Neutral Sentiment: Institutional positioning was mixed: 561 investors added shares while 802 reduced holdings. Large purchases by JPMorgan, Morgan Stanley and others were offset by reductions from BlackRock and Royal Bank of Canada, offering no clear consensus signal.
• Negative Sentiment: Revenue-headwind concerns remain the primary pressure on COR. Cencora’s lowered fiscal 2026 revenue-growth outlook reflects WAC and IRA-related price reductions, faster brand conversions at a major mail-order customer, slower GLP-1 growth and customer losses. Analyst target reductions after the outlook reset likely reinforced the recent decline. Cencora Slides as Investors Remain Cautious on Revenue Headwinds

Hedge Funds Weigh In On Cencora

A number of large investors have recently bought and sold shares of COR. State Street Corp lifted its position in shares of Cencora by 1.3% in the fourth quarter. State Street Corp now owns 9,305,507 shares of the company's stock valued at $3,142,935,000 after acquiring an additional 115,191 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Cencora by 80.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,661,769 shares of the company's stock worth $1,574,513,000 after acquiring an additional 2,085,473 shares during the period. Wellington Management Group LLP raised its holdings in shares of Cencora by 14.2% during the fourth quarter. Wellington Management Group LLP now owns 4,535,992 shares of the company's stock valued at $1,532,031,000 after acquiring an additional 564,871 shares during the period. Boston Partners boosted its stake in shares of Cencora by 2.0% during the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company's stock valued at $1,409,152,000 after buying an additional 89,506 shares during the period. Finally, Northern Trust Corp lifted its position in Cencora by 5.9% during the 3rd quarter. Northern Trust Corp now owns 2,272,464 shares of the company's stock worth $710,213,000 after acquiring an additional 126,929 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source